Mary Gospodarowicz

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5213819/publications.pdf

Version: 2024-02-01

430442 476904 1,670 32 18 29 citations g-index h-index papers 36 36 36 2456 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	Expanding global access to radiotherapy. Lancet Oncology, The, 2015, 16, 1153-1186.	5.1	709
2	The TNM classification of malignant tumoursâ€"towards common understanding and reasonable expectations. Lancet Oncology, The, 2017, 18, 849-851.	5.1	164
3	A prospective study of factors predicting clinically occult spinal cord compression in patients with metastatic prostate carcinoma. Cancer, 2001, 92, 303-310.	2.0	73
4	Prognostic factors in cancer. Journal of Surgical Oncology, 2003, 21, 13-18.	1.4	66
5	Primary Low-Grade B-Cell Lymphoma of Mucosa-Associated Lymphoid Tissue Type Arising in the Urinary Bladder. Archives of Pathology and Laboratory Medicine, 2001, 125, 332-336.	1.2	54
6	Global Consultation on Cancer Staging: promoting consistent understanding and use. Nature Reviews Clinical Oncology, 2019, 16, 763-771.	12.5	52
7	Curative-intent Metastasis-directed Therapies for Molecularly-defined Oligorecurrent Prostate Cancer: A Prospective Phase II Trial Testing the Oligometastasis Hypothesis. European Urology, 2021, 80, 374-382.	0.9	49
8	The principles of cancer staging. Ecancermedicalscience, 2016, 10, ed61.	0.6	47
9	Scale-up of radiotherapy for cervical cancer in the era of human papillomavirus vaccination in low-income and middle-income countries: a model-based analysis of need and economic impact. Lancet Oncology, The, 2019, 20, 915-923.	5.1	45
10	Global Task Force on Radiotherapy for Cancer Control. Lancet Oncology, The, 2015, 16, 1144-1146.	5.1	36
11	Global Radiotherapy: Current Status and Future Directions—White Paper. JCO Global Oncology, 2021, 7, 827-842.	0.8	35
12	Prognostic factors in clinical decision making. Cancer, 2001, 91, 1688-1695.	2.0	34
13	The need to expand global access to radiotherapy. Lancet Oncology, The, 2014, 15, 378-380.	5.1	32
14	Bringing Global Access to Radiation Therapy: Time for a Change in Approach. International Journal of Radiation Oncology Biology Physics, 2014, 89, 446-447.	0.4	27
15	Global impact of radiotherapy in oncology: Saving one million lives by 2035. Radiotherapy and Oncology, 2017, 125, 175-177.	0.3	27
16	Phase 2 trial of guideline-based postoperative image guided intensity modulated radiation therapy for prostate cancer: Toxicity, biochemical, and patient-reported health-related quality-of-life outcomes. Practical Radiation Oncology, 2015, 5, e473-e482.	1.1	24
17	Closing the Cancer Divide Through Ubuntu: Information and Communication Technology-Powered Models for Global Radiation Oncology. International Journal of Radiation Oncology Biology Physics, 2016, 94, 440-449.	0.4	23
18	Long-term outcomes of a phase II trial of moderate hypofractionated image-guided intensity modulated radiotherapy (IG-IMRT) for localized prostate cancer. Radiotherapy and Oncology, 2017, 122, 93-98.	0.3	23

#	Article	IF	CITATIONS
19	Management of testicular seminoma. , 1999, 17, 240-249.		21
20	Global patterns of <scp>nonâ€Hodgkin</scp> lymphoma in 2020. International Journal of Cancer, 2022, 151, 1474-1481.	2.3	20
21	Testicular Cancer Patients: Considerations in Long-Term Follow-Up. Hematology/Oncology Clinics of North America, 2008, 22, 245-255.	0.9	18
22	Improved outcomes with dose escalation in localized prostate cancer treated with precision image-guided radiotherapy. Radiotherapy and Oncology, 2017, 123, 459-465.	0.3	18
23	The Lancet Commission on cancer and health systems: harnessing synergies to achieve solutions. Lancet, The, 2021, 398, 1114-1116.	6.3	12
24	Tumor-targeted dose escalation for localized prostate cancer using MR-guided HDR brachytherapy (HDR) or integrated VMAT (IB-VMAT) boost: Dosimetry, toxicity and health related quality of life. Radiotherapy and Oncology, 2020, 149, 240-245.	0.3	10
25	Image Guided Radiation Therapy: Unlocking the Future Through Knowledge Translation. International Journal of Radiation Oncology Biology Physics, 2016, 96, 248-250.	0.4	8
26	[¹⁸ F]DCFPyL PET-MRI/CT for unveiling a molecularly defined oligorecurrent prostate cancer state amenable for curative-intent ablative therapy: study protocol for a phase II trial. BMJ Open, 2020, 10, e035959.	0.8	8
27	Principles of cancer staging. , 0, , 34-39.		8
28	Patient management scenario: A framework for clinical decision and prognosis. Journal of Surgical Oncology, 2003, 21, 8-12.	1.4	7
29	Principles of Cancer Staging for Clinical Obstetrics and Gynecology. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2015, 29, 767-775.	1.4	6
30	Transforming Canada's role in global cancer control. Lancet Oncology, The, 2021, 22, e400-e409.	5.1	6
31	Enhancing International Cancer Organization Collaborations: King Hussein Cancer Center and Princess Margaret Cancer Centre Model for Collaboration. Journal of Cancer Education, 2022, 37, 763-769.	0.6	2
32	TNM Staging of Prostate Cancer: Challenges in Securing a Globally Applicable Classification. European Urology, 2022, 82, e52-e53.	0.9	2